CA2028136A1 - Method and composition for treatment of periodontal disease - Google Patents
Method and composition for treatment of periodontal diseaseInfo
- Publication number
- CA2028136A1 CA2028136A1 CA 2028136 CA2028136A CA2028136A1 CA 2028136 A1 CA2028136 A1 CA 2028136A1 CA 2028136 CA2028136 CA 2028136 CA 2028136 A CA2028136 A CA 2028136A CA 2028136 A1 CA2028136 A1 CA 2028136A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- periodontal disease
- sodium
- allantoin
- chlorhexidine gluconate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/43—Guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
Abstract
A composition for treatment of periodontal disease includes an aqueous carrier of sterile water, glycerin and ethanol in which are present chlorhexidine gluconate, allantoin, sodium salicylate and sodium bicarbonate. A preferred method of treatment includes topical application to human periodontium in a mouthwash.
Description
. WO90/09779 2028136 PCT/US9~t~1041 i :`~
~.
t ~
?. , : ;
¦ METHOD AND COMPOSITION FOR TREATMENT !' OF PERIODONTAL DISEASE. _ .
BACKGROUND OF THE_INVENTION
Field of the Invention The present invention relates to a method and composition for treatment of periodontal disease and, more particularly, to a composition suitahle for topical application to prevent and treat~periodontitls.
:: ~
Descri~tion of the Prior Art ~ ~
Periodontal disease is the major cause of tooth loss in adults~ The periodontium is subj~ect to inflammation for many reasons, primary among them ~ei~g the accumulation of plaque deposits~under and above the gumline These~ ~
calcareous deposits of~organic and mineral matter, which ~ ~`
! : ~ consist~of micr;obial~colonies growing~in carbohydrate~
residues (from food), attach themselves to tooth surfaces~
and can, over time,~ alci~y into tartar. This hard ~;mineraliz~ed su~stance~adheres tenaciously~to the teeth~
~and~, when~under~the gumline, causes inflammation of the periodont~ium. ~Other causes of periodontitls~ can include ~ ~-malocclusion, food impaction and mouth breathlng.
Periodontitis~can cause~the gumline to retract due to~
supporting bone~;loss and the~;gums~to~bleed, and `even~ually, if not treated, can result in tooth loss~.
Until~now,~ the~only~known treatment for~periodon~it~is, outside of taklng~preventive~measures~to keep it from ;;
devel~oping in~the~fi~rst place, was~surgery. The accepted urglcal:procedure invol-eL removIng the Inrlamed gum ~ ~-WO90/09779 ~ 2~2~13~ PCTfUS90/01041 `~
~.
t ~
?. , : ;
¦ METHOD AND COMPOSITION FOR TREATMENT !' OF PERIODONTAL DISEASE. _ .
BACKGROUND OF THE_INVENTION
Field of the Invention The present invention relates to a method and composition for treatment of periodontal disease and, more particularly, to a composition suitahle for topical application to prevent and treat~periodontitls.
:: ~
Descri~tion of the Prior Art ~ ~
Periodontal disease is the major cause of tooth loss in adults~ The periodontium is subj~ect to inflammation for many reasons, primary among them ~ei~g the accumulation of plaque deposits~under and above the gumline These~ ~
calcareous deposits of~organic and mineral matter, which ~ ~`
! : ~ consist~of micr;obial~colonies growing~in carbohydrate~
residues (from food), attach themselves to tooth surfaces~
and can, over time,~ alci~y into tartar. This hard ~;mineraliz~ed su~stance~adheres tenaciously~to the teeth~
~and~, when~under~the gumline, causes inflammation of the periodont~ium. ~Other causes of periodontitls~ can include ~ ~-malocclusion, food impaction and mouth breathlng.
Periodontitis~can cause~the gumline to retract due to~
supporting bone~;loss and the~;gums~to~bleed, and `even~ually, if not treated, can result in tooth loss~.
Until~now,~ the~only~known treatment for~periodon~it~is, outside of taklng~preventive~measures~to keep it from ;;
devel~oping in~the~fi~rst place, was~surgery. The accepted urglcal:procedure invol-eL removIng the Inrlamed gum ~ ~-WO90/09779 ~ 2~2~13~ PCTfUS90/01041 `~
.. ..
..
` tissue, which is expensive and requires a long and painful recovery.
. ..
There have been Yarious attempts at treating periodontal ~--disease without such surgical intervention~ The ~est such ..
attempt to date resides in an oral rinse sold by Procter & ~ -Gamble under the name Peridex~. The chemistry of this product is described in the 1988 Physicans' Desk Reference at pages 1648-49. Unfortunately, Peridex~ rinse has not proved as efficacious ~gainst periodontal disease as might be desired and exhibits unwanted side effects, such as staining of tooth surfaces. -" ~,....
The following patents~also disclose oral treatment agents, but none is believed to represent a substitute for surgical intervention as a trea~ment for periodontal ~; disease:
~Re.31,397 ~ 4,213,961 2,684,924; ~ 4,332,7gl :: ~ ;3 j 887 ~ 712 4 r 339, 430 3,925,543 4,454,110 ~ !~
3,937,807 4,486,404 - ~
3,g57,967 4,569,837 ~ ;
..
` tissue, which is expensive and requires a long and painful recovery.
. ..
There have been Yarious attempts at treating periodontal ~--disease without such surgical intervention~ The ~est such ..
attempt to date resides in an oral rinse sold by Procter & ~ -Gamble under the name Peridex~. The chemistry of this product is described in the 1988 Physicans' Desk Reference at pages 1648-49. Unfortunately, Peridex~ rinse has not proved as efficacious ~gainst periodontal disease as might be desired and exhibits unwanted side effects, such as staining of tooth surfaces. -" ~,....
The following patents~also disclose oral treatment agents, but none is believed to represent a substitute for surgical intervention as a trea~ment for periodontal ~; disease:
~Re.31,397 ~ 4,213,961 2,684,924; ~ 4,332,7gl :: ~ ;3 j 887 ~ 712 4 r 339, 430 3,925,543 4,454,110 ~ !~
3,937,807 4,486,404 - ~
3,g57,967 4,569,837 ~ ;
4,051~234 4,601,900 4,067,962 4,661,342 4,198,392 Of interest;with regard to the present invention are U~.S.
Patent 4,486,404 which, in Example 5, discloses a ~`~
tdothpaste;containing chlorhexid;ine gluconate `and allantoin, U.S~. Patents 3,937,807 and 4,05~,234, which disc~lose mouthwashes~wlth~gluc~onates and anti~stain agents,~and U.S. Pa~ent 4,569,837, which discloses the use of~chlorhexidine gluconate and aspirin to treat perlodontal di~sease.~
W090~09779 PCT/U~90/0l0~1 - 20~136 ,.
., ~
SUMMA*Y OF THE INVENTION
It is an object of the present invention to provide a ' composition and method for treating Periodontitis I
; without costly and painful surgical intervention.
.~ .
In accordance with one aspect of the invention, a composition suitable for treating periodontitis comprises an a~ueous solution of an antimicrobial agent with bacteriacidal activity, an a~ent with therapeutic action against skin ulcers, an analgesic, a:stain remover and, if desired, suitable wetting agents, emulsifiers, dispersants, buffers stabilizers, preservatives, flavoring and coloring. -..
In accordance with another aspect of the invention, thecomposition i5 used in a treatment method which comprises the steps of topically applying the composition to inflamed periodonkium.
DESCRIPTION OF PREFERRED EMBODIMENTS
In a preferred embodimient of the invention the various components of the composition of the present invention are present in an aqueous carrier of sterile distilled water, gl.ycerine and ethanol. The glycerine provides thie composition with the desired feel an~ texture and the ethanol acts as an antiseptic.
.1'` ! ! I " I ' ` i , ~ ` i , To this water glycerine-ethanol:ca~rrier is added (1) chlorhexidîne gluconate (0.12% solution), C34H54Cl2N10Ol4 ! (Merck Index 2057j, as an antimicrobial agent with bacteriacldal action, (2):al1antoin,:or (2,5-dioxo-4- ~-imidazolidinyllurea (Merck Index 242) as an agent that ~:
..
,~. ~ ., ,. : ~ :
.J
~ :
'' I .
~ WO9~/0977~ . PCT/US9~J01041 2 ~ 1 ~ 6 - 4 ~
r .:
~ exhibits therapeutic action against skin ulcers, (3) .~ sodium salicylate, or 2-hydroxybenzoic acid monosodium . salt (Merck Index 8515), as an analgesic, and (4) sodium bicarbonate (Merck Index 8414) as a stain remover, along ~
with wetting agents, preservatives, emulsifiers, ~ dispersants, buffexs stabilizers, ~lavoring and coloring, .-t as desired (All references herein to the Merck Index refer to the 1~83 edition.) . .
In particularly preferred embodiment, the above ingredients are provided in the following proportions: -~
TABLE 1 ~;
''.. `' Sterile Water 70.77%
Glycerine (MI 4347) - 11.15% -Ethanol (MI 2~2) 7.50% ~ .
Polysorbate 80 :(as an emulsifier ~.
and dispersant; MI 7455) 4.20%
.
Chlorhexidine gluconate (0.12% -sol.) (MI 2057) 3.50% -~
Sodium bicarbonate (as a stain ;
remover; MI 8414) 0.50% l~.
Sodium lauryl sulfate (as a wetting agent; MI 8474~ 0.50% ~;
Vanilla (as flavoring; MI 9732) 0.60%
Saccharine~(as flavoring; MI~8170) 0.20~ ' ...
Sodium sali~ylate ~MI 8515) 0.15% ., ~i, Allantoin (MI 242) 0.63~% -Sodium ~enzoate (as a preservative; '-MI 8413) 0O10% `~:
, `-~
' ''`'"
. .;
. '""~.
, ...
~ W090~09779 ~ 0~ 1 3 6 P~CT/US90/01041 S
Xanthan gum (as a stabilizer and ~:
. emulsifier; MI 9868) 0.10% `
Sodium borate (as a buffer; MI 8421) 0.085%
F.D.& C. Blue (as coloring) 0.005%
F.D.& C. Red 40 (as coloring) 0.002%
f [Notes to Table l - (l) All proportions of the above ingredients are v/v; (2) "MI" refers to the Merck Index]
' The above composition is prepared by first measuring an appropriate quantity of sterile distilled water; for :
example, l000cc of the composition~ i5 to be prepared, 707.7cc of water are used. ~The remaining ingredients are added in the order listed in Table l, with each ingredient being thoroughly mixed by gently stirring the composition before the next ingredient is ad~ed. ~
,' A clinical test involving 30 people was performed using a composition similar to that set out above, except for using 72.77% sfterile water, 8.00% ethanol, 1.50%
chlorhexidine gluconate ff0.l2% solution) and 0.138%
allantoin. The subjects were chosen because~ all exhib~ited periodontal pockets up to 8mm or 9mm deep. Prior to beginning the treatment regimen, all 30 subjects agreed not to brush or floss their teeth for one week. Then, 15 :
cff the subjects rinsed their mouths three times a day with 1.0 cc of the abo~e composition 30 seconds before brushing and 15 rin~sed their mouths three ~imes a day with an equal amount of a colored sugar-water ~lacebo 30 seconds~before brushing. The sub~jects did not know whether they were uslng the inv~entive composition~or the placebo.
~ : : :: . :: ::
Once a week the teeth of each~subject were chec~ed for the - presence of plaque using a commercfially available plaque-'~ri'' ~ ~ disclosing solutio:n, Superdent'~ disclosing solution : .
:~.. ::
~i ~ ~: ~ ` ` : ' ,' W090/09779 PCT/US90/01041 ~
2 ~;~ g~
~,..`, - 6 - ~-.
concentrate, made by Rugby Laboratories, Inc., of ~' Rockville Centre, Long Island, NY 11570. All subjects using the inventive composition showed little or no plaque accumulation, while there was such plaque accumulation on the teeth of the subjects using the placebo.
The test procedures were continued for 12 weeks, and the subjects' conditions were measured in accordance with the Simplified Oral Hygiene Index (OHI-S) described in Orbanls Periodontics (3rd Ed. 1968~, The C.V. Mosby Co., St.
Louis, MO, at page 134. It was found that the average OHI-S for the subjects on the placebo went from 8mm to 9mm periodontal pocket depth to 6mm to 8mm pocket depth during the 12 week test, while that for the subjects using the inventive composition improved from 8mm to 9mm periodontal pocket depth to 2mm or 3mm pocket depth, which is considered within normal range.~
...
It is expected that~repeated use of the invPntive solution will reduce inflammation, stop bleeding and keratenize ;-damaged periodontal tissue. ,s Qf course, variations of the above preferred embodiment are possible within the scope of the present invention, such as ~arying the proportions of the chlorhexidine i gluconate, allantoin and sodium salicylate within ranges ! i that prov`ide efficacious results. It is intended by the claims appended below to include all such variations ~
i within the present invention.
: :' ., .", . ,, : : ' , . ...
`.'.,' . ", ,~
:~ .,
Patent 4,486,404 which, in Example 5, discloses a ~`~
tdothpaste;containing chlorhexid;ine gluconate `and allantoin, U.S~. Patents 3,937,807 and 4,05~,234, which disc~lose mouthwashes~wlth~gluc~onates and anti~stain agents,~and U.S. Pa~ent 4,569,837, which discloses the use of~chlorhexidine gluconate and aspirin to treat perlodontal di~sease.~
W090~09779 PCT/U~90/0l0~1 - 20~136 ,.
., ~
SUMMA*Y OF THE INVENTION
It is an object of the present invention to provide a ' composition and method for treating Periodontitis I
; without costly and painful surgical intervention.
.~ .
In accordance with one aspect of the invention, a composition suitable for treating periodontitis comprises an a~ueous solution of an antimicrobial agent with bacteriacidal activity, an a~ent with therapeutic action against skin ulcers, an analgesic, a:stain remover and, if desired, suitable wetting agents, emulsifiers, dispersants, buffers stabilizers, preservatives, flavoring and coloring. -..
In accordance with another aspect of the invention, thecomposition i5 used in a treatment method which comprises the steps of topically applying the composition to inflamed periodonkium.
DESCRIPTION OF PREFERRED EMBODIMENTS
In a preferred embodimient of the invention the various components of the composition of the present invention are present in an aqueous carrier of sterile distilled water, gl.ycerine and ethanol. The glycerine provides thie composition with the desired feel an~ texture and the ethanol acts as an antiseptic.
.1'` ! ! I " I ' ` i , ~ ` i , To this water glycerine-ethanol:ca~rrier is added (1) chlorhexidîne gluconate (0.12% solution), C34H54Cl2N10Ol4 ! (Merck Index 2057j, as an antimicrobial agent with bacteriacldal action, (2):al1antoin,:or (2,5-dioxo-4- ~-imidazolidinyllurea (Merck Index 242) as an agent that ~:
..
,~. ~ ., ,. : ~ :
.J
~ :
'' I .
~ WO9~/0977~ . PCT/US9~J01041 2 ~ 1 ~ 6 - 4 ~
r .:
~ exhibits therapeutic action against skin ulcers, (3) .~ sodium salicylate, or 2-hydroxybenzoic acid monosodium . salt (Merck Index 8515), as an analgesic, and (4) sodium bicarbonate (Merck Index 8414) as a stain remover, along ~
with wetting agents, preservatives, emulsifiers, ~ dispersants, buffexs stabilizers, ~lavoring and coloring, .-t as desired (All references herein to the Merck Index refer to the 1~83 edition.) . .
In particularly preferred embodiment, the above ingredients are provided in the following proportions: -~
TABLE 1 ~;
''.. `' Sterile Water 70.77%
Glycerine (MI 4347) - 11.15% -Ethanol (MI 2~2) 7.50% ~ .
Polysorbate 80 :(as an emulsifier ~.
and dispersant; MI 7455) 4.20%
.
Chlorhexidine gluconate (0.12% -sol.) (MI 2057) 3.50% -~
Sodium bicarbonate (as a stain ;
remover; MI 8414) 0.50% l~.
Sodium lauryl sulfate (as a wetting agent; MI 8474~ 0.50% ~;
Vanilla (as flavoring; MI 9732) 0.60%
Saccharine~(as flavoring; MI~8170) 0.20~ ' ...
Sodium sali~ylate ~MI 8515) 0.15% ., ~i, Allantoin (MI 242) 0.63~% -Sodium ~enzoate (as a preservative; '-MI 8413) 0O10% `~:
, `-~
' ''`'"
. .;
. '""~.
, ...
~ W090~09779 ~ 0~ 1 3 6 P~CT/US90/01041 S
Xanthan gum (as a stabilizer and ~:
. emulsifier; MI 9868) 0.10% `
Sodium borate (as a buffer; MI 8421) 0.085%
F.D.& C. Blue (as coloring) 0.005%
F.D.& C. Red 40 (as coloring) 0.002%
f [Notes to Table l - (l) All proportions of the above ingredients are v/v; (2) "MI" refers to the Merck Index]
' The above composition is prepared by first measuring an appropriate quantity of sterile distilled water; for :
example, l000cc of the composition~ i5 to be prepared, 707.7cc of water are used. ~The remaining ingredients are added in the order listed in Table l, with each ingredient being thoroughly mixed by gently stirring the composition before the next ingredient is ad~ed. ~
,' A clinical test involving 30 people was performed using a composition similar to that set out above, except for using 72.77% sfterile water, 8.00% ethanol, 1.50%
chlorhexidine gluconate ff0.l2% solution) and 0.138%
allantoin. The subjects were chosen because~ all exhib~ited periodontal pockets up to 8mm or 9mm deep. Prior to beginning the treatment regimen, all 30 subjects agreed not to brush or floss their teeth for one week. Then, 15 :
cff the subjects rinsed their mouths three times a day with 1.0 cc of the abo~e composition 30 seconds before brushing and 15 rin~sed their mouths three ~imes a day with an equal amount of a colored sugar-water ~lacebo 30 seconds~before brushing. The sub~jects did not know whether they were uslng the inv~entive composition~or the placebo.
~ : : :: . :: ::
Once a week the teeth of each~subject were chec~ed for the - presence of plaque using a commercfially available plaque-'~ri'' ~ ~ disclosing solutio:n, Superdent'~ disclosing solution : .
:~.. ::
~i ~ ~: ~ ` ` : ' ,' W090/09779 PCT/US90/01041 ~
2 ~;~ g~
~,..`, - 6 - ~-.
concentrate, made by Rugby Laboratories, Inc., of ~' Rockville Centre, Long Island, NY 11570. All subjects using the inventive composition showed little or no plaque accumulation, while there was such plaque accumulation on the teeth of the subjects using the placebo.
The test procedures were continued for 12 weeks, and the subjects' conditions were measured in accordance with the Simplified Oral Hygiene Index (OHI-S) described in Orbanls Periodontics (3rd Ed. 1968~, The C.V. Mosby Co., St.
Louis, MO, at page 134. It was found that the average OHI-S for the subjects on the placebo went from 8mm to 9mm periodontal pocket depth to 6mm to 8mm pocket depth during the 12 week test, while that for the subjects using the inventive composition improved from 8mm to 9mm periodontal pocket depth to 2mm or 3mm pocket depth, which is considered within normal range.~
...
It is expected that~repeated use of the invPntive solution will reduce inflammation, stop bleeding and keratenize ;-damaged periodontal tissue. ,s Qf course, variations of the above preferred embodiment are possible within the scope of the present invention, such as ~arying the proportions of the chlorhexidine i gluconate, allantoin and sodium salicylate within ranges ! i that prov`ide efficacious results. It is intended by the claims appended below to include all such variations ~
i within the present invention.
: :' ., .", . ,, : : ' , . ...
`.'.,' . ", ,~
:~ .,
Claims (8)
1. A composition for treating periodontal disease comprising an aqueous carrier having therein chlorhexidine gluconate, allantoin and sodium salicylate.
2. A composition according to claim 1, further comprising a stain remover.
3. A composition according to claim 2, wherein said stain remover is sodium bicarbonate.
4. A composition according to claim 1, wherein said chlorhexidine gluconate is present as a 0.12% solution and said aqueous carrier consists essentially of sterile water, glycerine and ethanol.
5. A composition for treating periodontal disease consisting essentially of the following ingredients in the following amounts according to volume:
Sterile Water 70.77%
Glycerine 11.15%
Ethanol 7.50%
Polysorbate 80 4.20%
Chlorhexidine gluconate (0.12% sol.) 3.50%
Sodium bicarbonate 0.50%
Sodium lauryl sulfate 0.50%
Sodium salicylate 0.15%
Allantoin 0.638%
Xanthan gum 0.10 Preservatives, buffers, flavoring and coloring 0.992%
Sterile Water 70.77%
Glycerine 11.15%
Ethanol 7.50%
Polysorbate 80 4.20%
Chlorhexidine gluconate (0.12% sol.) 3.50%
Sodium bicarbonate 0.50%
Sodium lauryl sulfate 0.50%
Sodium salicylate 0.15%
Allantoin 0.638%
Xanthan gum 0.10 Preservatives, buffers, flavoring and coloring 0.992%
6. A method for treating periodontal disease comprising the steps of:
providing a composition including an aqueous carrier having therein chlorhexidine gluconate, allantoin and sodium salicylate; and applying said composition topically to a human periodontium.
providing a composition including an aqueous carrier having therein chlorhexidine gluconate, allantoin and sodium salicylate; and applying said composition topically to a human periodontium.
7. A method according to claim 5, wherein the composition further includes a stain remover.
8. A method according to claim 6, wherein the stain remover is sodium bicarbonate.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31727189A | 1989-02-28 | 1989-02-28 | |
| US317,271 | 1989-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2028136A1 true CA2028136A1 (en) | 1990-09-29 |
Family
ID=23232900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2028136 Abandoned CA2028136A1 (en) | 1989-02-28 | 1990-02-28 | Method and composition for treatment of periodontal disease |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0423266A4 (en) |
| AU (1) | AU5287090A (en) |
| CA (1) | CA2028136A1 (en) |
| WO (1) | WO1990009779A1 (en) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1257345B (en) | 1992-06-02 | 1996-01-15 | HIGHLY EFFECTIVE SCLEROSANT SOLUTION, WHICH DOES NOT PRODUCE IATROGEN INJURY AND PROCEDURE TO OBTAIN THIS SOLUTION. | |
| US6486214B1 (en) | 1997-09-10 | 2002-11-26 | Rutgers, The State University Of New Jersey | Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
| US6468519B1 (en) | 1997-09-10 | 2002-10-22 | Rutgers, The State University Of New Jersey | Polyanhydrides with biologically active degradation products |
| US6673826B2 (en) | 1999-07-23 | 2004-01-06 | Alwyn Company, Inc. | Methods for treatment of inflammatory diseases |
| US6896897B2 (en) | 1999-07-23 | 2005-05-24 | Alwyn Company, Inc. | Flexible applicator for applying oil-in-water emulsion with improved stability |
| US6329413B1 (en) | 1999-07-23 | 2001-12-11 | Alwyn Company, Inc. | Allantoin-containing skin cream |
| US6864274B2 (en) | 1999-07-23 | 2005-03-08 | Alwyn Company, Inc. | Allantoin-containing skin cream |
| US6281236B1 (en) | 1999-07-23 | 2001-08-28 | Alwyn Company, Inc. | Oil-in-water emulsion with improved stability |
| US20020054895A1 (en) | 1999-07-23 | 2002-05-09 | Alwyn Company, Inc. | Allantoin-containing skin cream |
| US6531500B2 (en) | 1999-07-23 | 2003-03-11 | Alwyn Company, Inc. | Methods for treatment of inflammatory diseases |
| US20040038948A1 (en) | 1999-12-07 | 2004-02-26 | Uhrich Kathryn E. | Therapeutic compositions and methods |
| US6685928B2 (en) | 1999-12-07 | 2004-02-03 | Rutgers, The State University Of New Jersey | Therapeutic compositions and methods |
| DE60043075D1 (en) * | 1999-12-07 | 2009-11-12 | Univ Rutgers | THERAPEUTIC COMPOSITIONS AND METHOD FOR TREATING PERIODONTITIS WITH INFLAMMATORY MEDIUM-SUBSTANCES |
| CN103767886B (en) | 2005-11-09 | 2018-04-24 | 科洛斯科技公司 | Make the composition and method of dental whitening |
| EP2102144A4 (en) | 2006-09-13 | 2011-03-23 | Univ Rutgers | Active agents and their oligomers and polymers |
| US20100266989A1 (en) | 2006-11-09 | 2010-10-21 | Klox Technologies Inc. | Teeth whitening compositions and methods |
| MX337084B (en) | 2008-11-07 | 2016-02-10 | Klox Technologies Inc | Combination of an oxidant and a photoactivator for the healing of wounds. |
| CN102711831B (en) | 2009-07-17 | 2015-04-01 | 克洛克斯科技公司 | Antibacterial oral composition |
| US20140135372A1 (en) | 2010-02-02 | 2014-05-15 | Elliott Farber | Compositions and methods of treatment of inflammatory skin conditions using allantoin |
| US20130281913A1 (en) | 2012-04-20 | 2013-10-24 | Klox Technologies Inc. | Biophotonic compositions and methods for providing biophotonic treatment |
| US11116841B2 (en) | 2012-04-20 | 2021-09-14 | Klox Technologies Inc. | Biophotonic compositions, kits and methods |
| US9144579B2 (en) | 2012-08-17 | 2015-09-29 | Rutgers, The State University Of New Jersey | Polyesters and methods of use thereof |
| BR112015005593B1 (en) | 2012-09-14 | 2019-09-24 | Valeant Pharmaceuticals International, Inc. | Teeth Whitening Method |
| US20140120057A1 (en) | 2012-10-25 | 2014-05-01 | Rutgers, The State University Of New Jersey | Polymers and methods thereof for wound healing |
| US20140276354A1 (en) | 2013-03-14 | 2014-09-18 | Klox Technologies Inc. | Biophotonic materials and uses thereof |
| US9387250B2 (en) | 2013-03-15 | 2016-07-12 | Rutgers, The State University Of New Jersey | Therapeutic compositions for bone repair |
| US9862672B2 (en) | 2013-05-29 | 2018-01-09 | Rutgers, The State University Of New Jersey | Antioxidant-based poly(anhydride-esters) |
| EP3016686A4 (en) | 2013-07-03 | 2017-01-25 | Klox Technologies Inc. | Biophotonic compositions comprising a chromophore and a gelling agent for treating wounds |
| CN103893026B (en) * | 2014-03-31 | 2018-04-06 | 陈光健 | It is a kind of to be used for oral cleaning and the mouthwash of health care |
| EP3125963B1 (en) | 2014-04-01 | 2019-11-20 | Klox Technologies Inc. | Tissue filler compositions and methods of use |
| US10023521B2 (en) | 2014-06-13 | 2018-07-17 | Rutgers, The State University Of New Jersey | Process and intermediates for preparing poly(anhydride-esters) |
| ES2856841T3 (en) | 2014-10-31 | 2021-09-28 | Klox Tech Inc | Photoactivatable fibers and fabric media |
| WO2016164898A1 (en) | 2015-04-10 | 2016-10-13 | Rutgers, The State University Of New Jersey | Kojic acid polymers |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2529271C3 (en) * | 1975-07-01 | 1979-05-03 | Erich 2400 Luebeck Hofacker | Use of chlorhexidine and allantoin |
| US4370314A (en) * | 1975-12-08 | 1983-01-25 | Colgate-Palmolive Company | Oral composition containing antibacterial agent |
| IT1150603B (en) * | 1982-01-26 | 1986-12-17 | Ugo Baldacci | COMPOSITION FOR CLEANING AND DENTAL HYGIENE |
| US4454110A (en) * | 1982-05-24 | 1984-06-12 | Forsyth Dental Infirmary For Children | Self-gelling liquid composition for topical application in the oral cavity |
| US4512968A (en) * | 1982-11-30 | 1985-04-23 | Lion Corporation | Oral compositions |
| JPS59222406A (en) * | 1983-06-01 | 1984-12-14 | Teijin Ltd | Pharmaceutical preparation for remedying periodontosis and its preparation |
| WO1987005501A1 (en) * | 1986-03-17 | 1987-09-24 | Oral Research Laboratories, Inc. | Treatment of dental surfaces with plaque retardants |
-
1990
- 1990-02-28 EP EP19900905014 patent/EP0423266A4/en not_active Withdrawn
- 1990-02-28 CA CA 2028136 patent/CA2028136A1/en not_active Abandoned
- 1990-02-28 WO PCT/US1990/001041 patent/WO1990009779A1/en not_active Application Discontinuation
- 1990-02-28 AU AU52870/90A patent/AU5287090A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1990009779A1 (en) | 1990-09-07 |
| AU5287090A (en) | 1990-09-26 |
| EP0423266A1 (en) | 1991-04-24 |
| EP0423266A4 (en) | 1991-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2028136A1 (en) | Method and composition for treatment of periodontal disease | |
| Mandel | Antimicrobial mouthrinses: overview and update | |
| US4146607A (en) | Synergistic anti-plaque mixture with tetradecylamine plus aluminum and/or zinc | |
| US4097604A (en) | Method of treating and controlling gingivitis | |
| Twetman et al. | Effect of different chlorhexidine varnish regimens on mutans streptococci levels in interdental plaque and saliva | |
| US5073363A (en) | Foamable fluoride gels and method | |
| Bascones et al. | Influence of additional active ingredients on the effectiveness of non‐alcoholic chlorhexidine mouthwashes: a randomized controlled trial | |
| US4215144A (en) | Method of treating and controlling gingivitis | |
| Gjermo et al. | Antibacterial dentifrices: clinical data and relevance with emphasis on zinc/triclosan | |
| US4214006A (en) | Mouthwash and method for preventing and removing dental plaque | |
| CA1333692C (en) | Gel for optimum release of fluoride with antibacterial capability for use in the prevention of caries of root surface | |
| Holbeche et al. | A clinical trial of the efficacy of a cetylpyridinium chloride‐based mouth wash*: 1. Effect on plaque accumulation and gingival condition | |
| US6589513B2 (en) | Oral hygiene formulation and method of use | |
| Tinanoff et al. | Clinical and microbiological effects of daily brushing with either NaF or SnF2 gels in subjects with fixed or removable dental prostheses | |
| Lang et al. | Effect of chlorhexidine (0.12%) rinses on periodontal tissue healing after tooth extraction: (I). Clinical parameters | |
| US6110445A (en) | Oral composition exhibiting improved uptake and retention of antibacterial compounds on dental tissue surfaces | |
| US6497858B1 (en) | Method of remineralizing teeth | |
| Kjaerheim et al. | Experiments with triclosan-containing mouthrinses: dose response—and an attempt to locate the receptor site (s) of triclosan in the mouth | |
| CA1105388A (en) | Mouth-rinse solution containing ammonium fluoride | |
| ALMQVIST et al. | Gingival and mucosal reactions after intensive chlorhexidine gel treatment with or without oral hygiene measures | |
| US8871183B2 (en) | Composition for promoting and maintaining oral health | |
| JP2022058280A (en) | Composition for inhibiting plaque formation | |
| US20050180927A1 (en) | Novel anti-bacterial compositions | |
| JPH01502111A (en) | Oral hygiene medicine | |
| KR0170108B1 (en) | Toothpaste composition containing guaiac and coloring compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |